Published in Bone Marrow Transplant on January 04, 2016
A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | NCT01524978
Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (CART-138) | NCT01886976
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | NCT00689507
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | NCT02092922
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther (2016) 0.76
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. BMC Cancer (2017) 0.75
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Mol Ther Oncolytics (2016) 0.75
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther (2016) 0.75
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol (2016) 0.75
Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer (2017) 0.75
Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (2009) 20.49
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Multiple myeloma. N Engl J Med (2004) 10.81
Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem (1996) 10.70
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol (1995) 5.74
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol (2014) 3.62
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood (2013) 2.59
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett (2009) 2.28
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol (2014) 2.05
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood (2013) 2.01
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol (2010) 1.91
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A (2004) 1.85
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol (2013) 1.70
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood (2005) 1.66
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther (2011) 1.59
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood (2014) 1.47
HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol (2009) 1.45
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
A gene expression signature for high-risk multiple myeloma. Leukemia (2012) 1.36
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol (2006) 1.35
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood (2009) 1.32
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res (2011) 1.32
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol (1999) 1.26
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood (1996) 1.25
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer (2011) 1.20
Multiple myeloma: charging toward a bright future. CA Cancer J Clin (2007) 1.19
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant (2009) 1.14
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer (2006) 1.11
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant (2011) 1.10
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol (2014) 1.08
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant (1998) 1.03
Graft-versus-myeloma effect. Lancet (1996) 1.02
Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol (2007) 0.99
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer (2013) 0.96
Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma (2013) 0.96
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica (2012) 0.96
Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant (2012) 0.95
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica (2006) 0.95
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica (2009) 0.93
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol (2006) 0.93
Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol (2013) 0.91
Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia (2009) 0.91
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant (2011) 0.91
Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev (2014) 0.91
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant (2010) 0.90
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol (2009) 0.90
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood (2011) 0.90
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics (2014) 0.89
Darwinian evolution and tiding clones in multiple myeloma. Blood (2012) 0.89
Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol (2004) 0.89
Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant (2012) 0.88
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol (2012) 0.88
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia (2012) 0.88
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J (2015) 0.87
Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol (2006) 0.87
Medicine. How thalidomide works against cancer. Science (2014) 0.87
Current and emerging treatment options for patients with relapsed myeloma. Clin Med Insights Oncol (2013) 0.86
The allogeneic dilemma. Bone Marrow Transplant (2007) 0.85
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol (2014) 0.83
Re-transplantation after bortezomib-based therapy. Br J Haematol (2011) 0.82
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol (2006) 0.81
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Ann Hematol (2011) 0.80
Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant (1999) 0.79